Introduction
During the past decade, decreased susceptibility to carbapenems has been increasingly reported worldwide in Gram-negative clinical isolates including Enterobacteriaceae, Pseudomonas spp. and Acinetobacter spp. In Enterobacteriaceae, carbapenem resistance may result either from the combination of decreased outer-membrane permeability with overexpression of b-lactamases possessing no (or very weak) carbapenemase activity or from a b-lactamase with strong hydrolytic activity towards carbapenems, i.e. a carbapenemase. 1, 2 In Enterobacteriaceae, the carbapenemases are in most cases an Ambler class A b-lactamase (KPC type), 3 an Ambler class B b-lactamase (metallo-b-lactamases of VIM, IMP 1, 2 and NDM types) 4 or an Ambler class D b-lactamase (OXA-48 type). 5 Usually, carbapenemase-producing Enterobacteriaceae (CPE) are resistant to many other b-lactam and non-b-lactam antibiotics, giving rise to MDR and sometimes pandrug-resistant isolates.
As a consequence, the spread of carbapenemase producers represents a serious threat to public health as treatment options are very reduced. In addition, as very few new antibiotics are being introduced into the market, it is important to prevent the further spread of carbapenemase producers by rapidly identifying a specific resistance mechanism. 6 During the past two years, several novel technologies have been proposed for the rapid detection of carbapenemase producers. They include: (i) methods able to detect the production of a carbapenem-hydrolysing activity such as the Carba NP test and its derivatives 7 -10 and MALDI-TOF MS protocols 11 ; and (ii) molecular techniques able to detect the main carbapenemase-encoding genes. 12 Although some of these techniques may be performed directly on clinical samples (e.g. blood cultures, stools), they are most often used as complementary tests that are performed on bacterial colonies after antimicrobial susceptibility testing results. 
Materials and methods

Clinical isolates
From April 2014 to June 2014, 621 non-duplicate clinical enterobacterial isolates with reduced susceptibility to carbapenems were received at the French National Reference Centre for Antibiotic Resistance. The isolates were re-identified at the species level using Bruker Biotyper MALDI-TOF MS system (Bruker Daltonique, Wissembourg, France).
Susceptibility testing and algorithm for screening of non-carbapenemase producers Susceptibility testing was performed by the disc diffusion method on Mueller -Hinton agar plates (Bio-Rad) incubated for 18 h at 35+18C according to EUCAST guidelines, as updated in 2014 (http://www.eucast. org/). All tested isolates were non-susceptible to at least one of the three carbapenem molecules (imipenem, meropenem and ertapenem) according to the CA-SFM guidelines (inhibition diameters of ,25 mm, ,23 mm and ,25 mm for meropenem, imipenem and ertapenem, respectively). Inhibition zone diameters of ticarcillin/clavulanate (75/ 10 mg), temocillin (30 mg) and imipenem (10 mg) (Oxoid, Dardill, France) were measured and subjected to the algorithm. In this algorithm, as proposed by the CA-SFM and outlined in Figure 1 , the cut-offs used for zone diameters of imipenem, ticarcillin/clavulanate and temocillin were 22 mm, 15 mm and 15 mm, respectively.
The CA-SFM algorithm was compared with EUCAST guidelines (http:// www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Resistance_ mechanisms/EUCAST_detection_of_resistance_mechanisms_v1.0_ 20131211.pdf) and CLSI clinical breakpoints, 13 for the screening of CPE.
Characterization of the mechanisms responsible for decreased carbapenem susceptibility
All isolates were tested for imipenem hydrolysis using the updated version of the Carba NP test as previously reported. 7 Simplex PCRs for detection of bla KPC , bla IMI , bla SME , bla GES , bla VIM , bla IMP , bla NDM , bla GIM and bla OXA-48-like carbapenemase genes were performed for all isolates using primers previously described.
14 All PCR products were sequenced in order to determine the exact nature of the carbapenemase genes. Results of PCR and sequencing were used as gold standards for the evaluation of the other detection techniques. For bacterial isolates that had negative results from a Carba NP test and that had negative results from all PCRs, decreased carbapenem susceptibility due to overexpression of a cephalosporinase (chromosome encoded or plasmid acquired) was suspected for isolates having carbapenem susceptibility restored on Mueller -Hinton agar supplemented with 200 mg/L cloxacillin. Concerning decreased carbapenem susceptibility due to the overexpression of a cephalosporinase (chromosome encoded or plasmid acquired) plus the co-expression of an ESBL, the ESBL production was evidenced by double disc synergy performed on cloxacillin-supplemented medium as previously described. 15 In addition, decreased outer-membrane permeability was revealed by reduced susceptibility to moxalactam (inhibition zone diameter of ,23 mm for 30 mg of moxalactam). 16 
Results
From April 2014 to June 2014, 621 non-duplicate clinical Enterobacteriaceae with reduced susceptibility to carbapenems were received at the French National Reference Centre for Antibiotic Resistance (Table 1) . Seven species represented 96.2% of the isolates. Klebsiella pneumoniae, Enterobacter cloacae, Escherichia coli, Citrobacter freundii, Enterobacter aerogenes, Klebsiella oxytoca and Proteus mirabilis represented 38.5%
.3% (n ¼ 14) and 1.4% (n ¼ 9) of the isolates, respectively (Table 1 ). All isolates possessed decreased susceptibility to at least one of the three carbapenems tested (imipenem, ertapenem and meropenem). Although ertapenem was constantly categorized as intermediate or resistant, imipenem and meropenem were most often categorized as susceptible or intermediate according to EUCAST guidelines. Accordingly, tested enterobacterial isolates were more resistant to ertapenem than imipenem or meropenem, except six P. mirabilis isolates and one Morganella morganii isolate, which were resistant to imipenem but susceptible to ertapenem and meropenem (Table 1) . This phenotype was attributed to the natural low susceptibility to imipenem of Proteae plus decreased outer-membrane permeability (Table 1 ). Among the 621 tested isolates, 213 (34.8%) produced a carbapenemase, as revealed by a positive Carba NP test. However, this percentage of CPE varied a lot depending on the bacterial species. Indeed, 55.0% (132/240) of K. pneumoniae and 49.0% (51/104) of E. coli isolates produced a carbapenemase, while this percentage was only 9%, 9.5%, 11.1%, 13.6% and 14.3% for E. cloacae, E. aerogenes, P. mirabilis, C. freundii and K. oxytoca isolates, respectively (Table 1 ). PCR analysis revealed that the most prevalent carbapenemases were OXA-48-like enzymes (85.6%), followed by NDM (9.7%), VIM (1.9%) and KPC (1.4%). Most of the CPE expressed a single carbapenemase, except one K. pneumoniae and two E. coli isolates that were positive for NDM-1 + OXA-48, NDM-1 +OXA-232 and NDM-1 + VIM-2, respectively (Table 1 ). In the absence of carbapenemase production, the decreased susceptibility to carbapenems was considered to result from decreased outer-membrane permeability associated with the expression of a b-lactamase with a weak hydrolytic activity against carbapenems. As expected, overexpression of the chromosome-encoded cephalosporinase was mostly involved in E. cloacae (59.9%), E. aerogenes (84.2%) and C. freundii (78.9%) isolates, whereas ESBL production was predominant in K. pneumoniae (89.9%) and E. coli (62.3%) isolates (Table 1) .
Applied to our prospective collection of 621 Enterobacteriaceae with decreased susceptibility to carbapenems, the algorithm had an NPV and a sensitivity of 100% (Table 2) . Indeed, this algorithm perfectly identified all the 204 non-carbapenemase-producing Dortet et al.
isolates (32.9%) without the performance of any complementary testing. Of note, all of the 185 OXA-48-like-producing strains had a diameter ,15 mm for temocillin. In EUCAST guidelines, the temocillin cut-off value was ,11 mm. However, in our study, 9 OXA-48-like producers (4.9% of the OXA-48-like producers) possessed an inhibition diameter that ranged from 11 to 13 mm.
Based on EUCAST recommendations that propose a unique carbapenem disc (meropenem or imipenem or ertapenem) for the screening of CPE, the NPVs were 95.7%, 99.3%, 87.4% and 96.7% using screening cut-offs of 25 mm for meropenem, 27 mm for meropenem, 23 mm for imipenem and 25 mm for ertapenem, respectively (Table 2 ). In addition, based on CLSI clinical breakpoints of meropenem (I/R ,23 mm), imipenem (I/R ,23 mm) and ertapenem (I/R ,22 mm) for the screening of CPE, 13 the NPVs were 86.3%, 87.4% and 94.5%, respectively ( Table 2 ).
Discussion
Compared with what was observed in 2012 on 1485 Enterobacteriaceae, 15 we noticed a significant (x 2 , P, 0.05) increase in the frequency of E. coli (16.4% in 2014 versus 12.7% in 2012) among Enterobacteriaceae with decreased susceptibility to carbapenems. In contrast, a significant decrease (x 2 , P,0.05) was observed for E. cloacae (30.4% in 2014 versus 42.2% in 2012), while the difference for K. pneumoniae was not significant (38.5% in 2014 versus 35.2% in 2012). In addition, the percentage of CPE was significantly higher in our study than what was observed in France in 2012 (34.8% in 2014 versus 22.9% in 2012), suggesting either the emergence of CPE or better screening of the isolates sent to the French National Reference Centre for Antibiotic Resistance, but the total number of CPE was higher in 2014, which supports the emergence of CPE. 15 In addition, although Total  138  169  77  21  2  1  15  6  3  1  166  1  8  9  1  1  1  1  621 a Production of an ESBL plus decreased outer-membrane permeability (Imper) as revealed by reduced susceptibility to moxalactam. b Production of a cephalosporinase plus decreased outer-membrane permeability as revealed by reduced susceptibility to moxalactam. c Production of an ESBL, production of a cephalosporinase (Case) plus decreased outer-membrane permeability as revealed by reduced susceptibility to moxalactam. d For the K. pneumoniae and the 3 E. cloacae isolates, decreased outer-membrane permeability as revealed by reduced susceptibility to moxalactam was involved; for the 10 K. oxytoca isolates, decreased susceptibility to carbapenems resulted from overexpression of the bla OXY gene plus decreased outer-membrane permeability as revealed by reduced susceptibility to moxalactam; and for the 6 P. mirabilis and the M. morganii isolates, decreased susceptibility to carbapenems corresponded to the natural low susceptibility to imipenem associated with decreased outer-membrane permeability as revealed by reduced susceptibility to moxalactam.
the percentage of CPE varied a lot depending on the bacterial species, a significant increase of the CPE frequency among E. coli (49.0% in 2014 versus 28.2% in 2012) was noticed. Since E. coli is more often considered to be responsible for communityacquired infections than K. pneumoniae or E. cloacae, which are mostly nosocomial pathogens, our results suggest a community dissemination of CPE in France. In the context of the emergence of Enterobacteriaceae that are not susceptible to carbapenems in the community, it is of utmost importance to have a highly sensitive method that can clearly discriminate strains that do not produce carbapenemase from strains that require complementary testing. In cases of infections with such isolates, results of the routine antibiogram are rapidly available and could thus be used to discriminate between isolates requiring additional testing from those negative for carbapenemases. Our results validate the excellent (100%) NPV of the algorithm proposed by the CA-SFM for the screening of non-carbapenemase producers among Enterobacteriaceae with decreased susceptibility to carbapenems (Table 2 ). Based on the zone diameters measured around ticarcillin/clavulanate, temocillin and imipenem discs, 32.9% of the isolates could be classified as non-carbapenemase producers without any further testing. In this prospective study, we identified only three isolates with ticarcillin/clavulanate ≥15 mm and imipenem ,22 mm that required complementary tests (Figure 1 ). In addition, these three isolates were all noncarbapenemase producers (two Enterobacter aerogenes that overexpressed their chromosomal AmpC and one ESBL-producing Enterobacter cloacae that also overexpressed its chromosomal AmpC). Accordingly, the CA-SFM algorithm might be simplified without any consequence to the NPV (100%). Indeed, our results suggested that it was not necessary to test imipenem on strains with an inhibition zone of ≥15 mm for ticarcillin/clavulanate but that, instead, all such strains should just be considered noncarbapenemase producers. Screening cut-off values of 25 mm, 23 mm and 25 mm for meropenem, ertapenem and imipenem, respectively, have been defined by EUCAST to detect CPE, whereas CLSI proposes clinical breakpoints of 23 mm, 23 mm and 21 mm for meropenem, imipenem and ertapenem, respectively. 13 Based on EUCAST recommendations, the NPVs were 95.7%, 87.4% and 96.7% using screening cut-offs of 25 mm for meropenem, 23 mm for imipenem and 25 mm for ertapenem, respectively ( Table 2) . As previously observed, meropenem has been determined to offer the best compromise between sensitivity and specificity in terms of detecting carbapenemase producers. 17 -19 In addition in EUCAST guidelines, a screening cut-off of 27 mm for meropenem has been proposed in countries where OXA-48 producers are highly prevalent, which is the case in France. Using this cut-off value, the NPV was 99.3% (Table 2 ). However, only 22.2% of the isolates (138/621), versus 32.9% with the CA-SFM algorithm, could be classified as non-carbapenemase producers without any further testing, and one OXA-48-producing E. coli was falsely considered a non-carbapenemase producer. As previously observed by Maurer et al., 17 using CLSI clinical breakpoints, the best NPV was obtained using ertapenem (94.5%) compared with meropenem (86.3%) and imipenem (87.4%) ( Table 2) . Furthermore, as previously observed, we confirmed that EUCAST cut-offs used for detection of CPE gave better results than CLSI clinical breakpoints (Table 2) . 17 The high prevalence of OXA-48 producers in European countries compared with that in the USA might explain this difference. Finally, compared with EUCASTand CLSI guidelines, the CA-SFM algorithm possessed the best NPV and sensitivity to detect carbapenemase producers (Table 2) . 17, 20 Accordingly, EUCAST defined a cut-off value of 11 mm as an efficient indicator of the production of OXA-48-like enzymes. In the CA-SFM algorithm, this cut-off was 15 mm. Our results demonstrated that a temocillin cut-off of 15 mm was able to detect all OXA-48-like producers, while it failed to detect 4.9% (9/185) of the OXA-48-like producers when this cut-off was decreased to 11 mm.
Although several tests have been recently developed for the rapid detection (,2 h) of carbapenemase activity [such as (i) the Carba NP test 7, 9 and its commercialized derivatives (RAPIDEC w CARBA NP, bioMérieux and Rapid CARB Screen w , ROSCO Diagnostic) 8, 10 ; (ii) MALDI-TOF MS technology 11 ; and (iii) the molecular detection of the main carbapenemase-encoding genes 12 ] the use of this algorithm might result in a gain of time and in a reduced cost for clinical microbiology laboratories, since complementary testing would be necessary only in two-thirds of the cases. However, such screening requires several conditions. First, the susceptibility testing has to be performed using disc diffusion methods, which is not the common practice for most laboratories, where automated liquid methods are usually used for susceptibility testing. Secondly, the three discs that contain antimicrobials (ticarcillin/clavulanate, imipenem and temocillin) have to be routinely and directly tested for all Enterobacteriaceae. However, according to the CA-SFM, only imipenem is part of the mandatory list of antibiotics that have to be tested for all Enterobacteriaceae. Ticarcillin/ clavulanate is part of the complementary list and temocillin is not included in any list of antibiotics to be tested for Enterobacteriaceae. Finally, the CA-SFM algorithm is not of interest in cases of screening samples. Indeed, CPE screening samples (mostly rectal swabs) are spread on selective agar and require 18 -24 h to yield colonies. De facto, these colonies are suspected to be CPE and should be immediately processed using rapid complementary tests without waiting for the antibiogram results, which would take an additional 18 h and eliminate only 30% of the isolates.
